Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 6/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663239 | 0.94 | CNR2 (0.44) | CYP1A2CYP2D6CYP2C19CNR2CNR1 | |
| SCHEMBL4663080 | 0.86 | CNR2 (0.48) | CNR2CNR1MEN1KMT2AMDM2 | |
| SCHEMBL4666707 | 0.85 | PKM (0.39) | CYP2D6CYP2C19CNR2ALDH1A1KMT2A | |
| SCHEMBL4664924 | 0.81 | ALDH1A1 (0.43) | CNR2CNR1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4663078 | 0.79 | PTPN1 (0.41) | CYP2D6CYP2C19CNR2ALDH1A1MEN1 | |
| SCHEMBL4663079 | 0.79 | ALDH1A1 (0.47) | CNR2CNR1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4663356 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4663362 | 0.78 | NR5A2 (0.48) | ALDH1A1MDM2 | |
| SCHEMBL4664758 | 0.77 | ALDH1A1 (0.42) | CYP2D6CYP2C19ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4664875 | 0.76 | POLB (0.52) | ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | claimed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | CYP1A2 2117/4885CYP2D6 2202/4885CYP2C19 1751/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | CYP1A2 2117/4885CYP2D6 2202/4885CYP2C19 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.